Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study

Diabetes, Obesity and Metabolism

Volumn 18, Issue 9, 2016, Pages 925-929

  Kaku, K ^a   Enya, K ^b   Nakaya, R ^b   Ohira, T ^b   Matsuno, R ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

fasiglifam; FFA1 receptor agonist; GPR40 agonist; TAK 875; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FASIGLIFAM; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; BENZOFURAN DERIVATIVE; BIGUANIDE DERIVATIVE; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONE; TAK-875;

ABNORMAL LABORATORY RESULT; ADULT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; LETTER; LONG TERM CARE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; AGONISTS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE BLOOD LEVEL; JAPAN; LIVER; MALE; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

BENZOFURANS; BIGUANIDES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLYCOSIDE HYDROLASE INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; JAPAN; LIVER; MALE; MIDDLE AGED; RECEPTORS, G-PROTEIN-COUPLED; SULFONES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84978386144     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12693     Document Type: Letter

References (12)

1. Feng XT, Leng J, Xie Z, Li SL, Zhao W, Tang QL. GPR40: a therapeutic target for mediating insulin secretion (review). Int J Mol Med 2012; 30: 1261–1266.
2. Watterson KR, Hudson BD, Ulven T, Milligan G. Treatment of type 2 diabetes by free fatty acid receptor agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
3. Negoro N, Sasaki S, Mikami S et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 2010; 1: 290–294.
4. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14: 271–278.
5. Leifke E, Naik H, Wu J et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther 2012; 92: 29–39.
6. Burant CF, Viswanathan P, Marcinak J et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012; 379: 1403–1411.
7. Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 2013; 36: 245–250.
8. Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 2015; 17: 675–681.
9. Kashiwagi A, Kasuga M, Araki E, for the Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig 2012; 3: 39–40.
10. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Guideline for clinical evaluation of oral hypoglycemic agents. PFSB/ELD Notification No. 0709-1, 9 July 2010.
11. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Questions and answers (Q&As) regarding the guideline for clinical evaluation of oral hypoglycemic agents. Administrative notice, 9 July 2010.
12. Takeda Press Release. Takeda announces termination of fasiglifam (TAK-875) development. 26 December 2013. Available from URL: http://www.takeda.us/newsroom/press_release_detail.aspx?year=2013&id=296. Accessed 15 March 2016.